Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
Stock
CRVS
CRVS News & Events
-
Add to Watchlist
Trade CRVS
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Forecast
Technical
Valuation
Financials
Earnings
Should I Buy
News
CRVS News
Analysis of Corvus Pharmaceuticals Put Selling
5 days ago
NASDAQ.COM
Momentum Is Beginning for These 3 Fast-Growing Stocks in 2026
6 days ago
Marketbeat
Corvus Pharmaceuticals (CRVS) Stock Soars 211.8% to New All-Time High
Jan 26 2026
Yahoo Finance
Corvus Pharmaceuticals Upsizes Stock Offering to $175 Million for R&D and Working Capital
Jan 22 2026
stocktwits
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials
Jan 22 2026
seekingalpha
Corvus Pharmaceuticals Prices Upsized Offering of 7.9 Million Shares at $22.15, Raising $175 Million
Jan 22 2026
Yahoo Finance
Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
Jan 21 2026
Benzinga
Corvus Pharmaceuticals Initiates $150 Million Public Offering Amid 8.92% Stock Decline
Jan 21 2026
NASDAQ.COM
Show More News
CRVS Events
01/22 08:40
Jefferies and Goldman Sachs Increase Deal Size to $175M
The deal size was increased to $175M in common stock from $150M in common stock. Jefferies and Goldman Sachs acted as joint book running managers for the offering.
Show More Events
CRVS Monitor News
Corvus Pharmaceuticals Prices $175M Upsized Public Offering
Jan 26 2026
Corvus Pharmaceuticals Reports Positive Trial Results and Upsizes Stock Offering
Jan 22 2026
Corvus Pharmaceuticals to Report Phase 1 Trial Results for Soquelitinib
Jan 20 2026
CRVS Earnings Analysis
No Data
People Also Watch
